文献速递临床试验与 GCP真实世界研究与卫生经济

静脉曲张治疗随机试验的五年结局

Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins.
PubMed 文献 · N Engl J Med · 2019-01-01

这项在英国11个中心开展的随机对照试验纳入798例原发性静脉曲张患者,比较激光消融、泡沫硬化疗法与手术的5年结局。结果显示,激光消融或手术后的疾病特异性生活质量优于泡沫硬化疗法,通用生活质量在各组间无差异;在每QALY支付意愿阈值20000英镑(28433美元)下,多数成本效果模型迭代支持激光消融。

要点

  • 5年时激光消融和手术的Aberdeen静脉曲张问卷评分均低于泡沫硬化疗法,疾病特异性生活质量更优。
  • 通用生活质量指标在各治疗组间无差异。
  • 每QALY支付意愿阈值20000英镑(28433美元)下,77.2%的成本效果模型迭代支持激光消融。

核心结论

  • 在静脉曲张治疗的随机试验中,治疗后5年激光消融或手术的疾病特异性生活质量优于泡沫硬化疗法。
  • 在每QALY支付意愿阈值20000英镑(28433美元)下,多数概率成本效果模型迭代支持激光消融。

研究设计与样本

  • 随机对照试验,纳入英国11个中心的798例原发性静脉曲张参与者,比较激光消融、泡沫硬化疗法与手术的结局。

主要发现

  • 798例试验参与者中595例(75%)完成了生活质量问卷。
  • 校正基线评分及其他协变量后,激光消融组与泡沫硬化疗法组的Aberdeen静脉曲张问卷评分调整差值(效应量)为-2.86(95%CI,-4.49至-1.22;P<0.001),手术组与泡沫硬化疗法组的调整差值为-2.60(95%CI,-3.99至-1.22;P<0.001);该问卷评分范围0至100,评分越低表示生活质量越好。
  • 通用生活质量指标在各治疗组间无差异。
  • 在每QALY支付意愿阈值20000英镑(28433美元)下,77.2%的成本效果模型迭代支持激光消融。
  • 在泡沫硬化疗法与手术的两两比较中,54.5%的模型迭代支持手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovenous laser ablation and ultrasound-guided foam sclerotherapy are recommended alternatives to surgery for the treatment of primary varicose veins, but their long-term comparative effectiveness remains uncertain. METHODS: In a randomized, controlled trial involving 798 participants with primary varicose veins at 11 centers in the United Kingdom, we compared the outcomes of laser ablation, foam sclerotherapy, and surgery. Primary outcomes at 5 years were disease-specific quality of life and generic quality of life, as well as cost-effectiveness based on models of expected costs and quality-adjusted life-years (QALYs) gained that used data on participants' treatment costs and scores on the EuroQol EQ-5D questionnaire. RESULTS: Quality-of-life questionnaires were completed by 595 (75%) of the 798 trial participants. After adjustment for baseline scores and other covariates, scores on the Aberdeen Varicose Vein Questionnaire (on which scores range from 0 to 100, with lower scores indicating a better quality of life) were lower among patients who underwent laser ablation or surgery than among those who underwent foam sclerotherapy (effect size [adjusted differences between groups] for laser ablation vs. foam sclerotherapy, -2.86; 95% confidence interval [CI], -4.49 to -1.22; P<0.001; and for surgery vs. foam sclerotherapy, -2.60; 95% CI, -3.99 to -1.22; P<0.001). Generic quality-of-life measures did not differ among treatment groups. At a threshold willingness-to-pay ratio of £20,000 ($28,433 in U.S. dollars) per QALY, 77.2% of the cost-effectiveness model iterations favored laser ablation. In a two-way comparison between foam sclerotherapy and surgery, 54.5% of the model iterations favored surgery. CONCLUSIONS: In a randomized trial of treatments for varicose veins, disease-specific quality of life 5 years after treatment was better after laser ablation or surgery than after foam sclerotherapy. The majority of the probabilistic cost-effectiveness model iterations favored laser ablation at a willingness-to-pay ratio of £20,000 ($28,433) per QALY. (Funded by the National Institute for Health Research; CLASS Current Controlled Trials number, ISRCTN51995477.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Brittenden J, Cooper D, Dimitrova M, et al. Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins. N Engl J Med. 2019. PMID: 31483962. doi:10.1056/NEJMoa1805186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。